Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L6 + interleukin-2
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
L6 + interleukin-2 is a combination immunotherapy approach that combines murine monoclonal antibody L6 (MoAb L6) with subcutaneous interleukin-2 (IL-2). This combination was investigated in a phase I clinical trial for patients with refractory adenocarcinoma, where L6 was administered at 200 mg/m² intravenously daily for 7 days, followed by a one-week rest period, and then IL-2 was given subcutaneously at doses ranging from 2 to 4.5 × 10⁶ U/m² daily for 4 days over 3 weeks. The combination showed immunomodulatory effects and was generally well-tolerated in the outpatient setting.
- Other names
- MoAb L6 + IL-2murine monoclonal antibody L6 + interleukin-2L6 + IL-2L6 + SC IL-2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on L6 + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L6 + interleukin-2.